Expression of galactosyltransferase in prostatic tumors

Galactosyltransferase (GalTase) has been discovered on a variety of cells where it is believed to be involved in cell-cell adhesion and cell-substratum adhesion as well as in metastasis of carcinoma cells. This immunohistochemical study was undertaken to identify the topography and the cellular distribution of GalTase in normal prostatic tissue, benign prostatic hyperplasia (11 cases), and prostatic carcinoma (26 cases). Immunoreactive GalTase was found to be exclusively associated with carcinoma cells and with premalignant epithelial cells in prostatic hyperplasia. In highly differentiated carcinomas, most of the carcinoma cells are positive for GalTase, whereas in poorly differentiated tumors, GalTase immunoreactivity was restricted to a subset of carcinoma cells with obviously invasive behavior. At the cellular level, GalTase was localized in the cytoplasm and at the cell membrane. In sections of normal prostatic tissue, as well as in unaltered acini of prostatic hyperplasic tissue, GalTase was not expressed. Fibroblasts, smooth muscle cells, and endothelial cells of the prostatic stroma were also consistently negative. With the use of immunoblots, we could confirm the presence of GalTase with a molecular mass of 45 kDa in the extracts of benign prostatic hyperplasic tissue and in prostatic carcinoma tissue but not in normal prostatic tissue. The results of our immunohistochemical study suggest that GalTase is a valuable marker to diagnose neoplastic transformation in prostatic tissue.